Compare Gilead Sciences, Inc. (GILD) vs Marriott International Inc (MAR) Price & Performance

Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.

Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.

Marriott International (MAR) trades at $371.50, up 2.29% today, with a bearish technical signal despite recent earnings beats. The company maintains strong revenue growth, reaching $26.19B in 2025, with a net income margin of 9.72%. Recent developments include the launch of Ask Bonvoy AI and reaching 10,000 global properties. Analyst consensus is mixed with 44% buy ratings but a price target of $387.33 suggesting modest upside potential.

MAR shows solid operational performance with consistent cash flow generation, though high debt levels and negative shareholder equity present risks. The stock faces headwinds from technical bearish signals and hotel owner disputes over loyalty programs. Upside potential exists from travel recovery and strategic partnerships, but investors should weigh valuation concerns against growth prospects.